Chief Scientific Officer · Fulcrum Therapeutics, Inc. (FULC)

Owen Wallace

FY2019 is the first fiscal year CompBrief holds for Owen Wallace as a named executive officer of Fulcrum Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$1,559,523

Salary $381,465Stock awards $0Bonus $126,000

2nd of 3 named executive officers at Fulcrum Therapeutics by FY2019 total.

3 named officers on file for Fulcrum Therapeutics, FY2019

Owen Wallace’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Fulcrum Therapeutics’s whole pay program stands against its peers

  • Fulcrum Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FULC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2020 (DEF 14A).

Free

Get Owen Wallace’s full pay file as a PDF — free

More than this page: up to 10 years of Owen’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Owen Wallace compensation by year

Fulcrum Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Fulcrum Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$381,465
Bonus$126,000
Stock awards$0
Option awards$1,052,059
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$1,559,523

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Fulcrum Therapeutics, Inc. DEF 14A filed April 29, 2020, accession 0001193125-20-124813, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Fulcrum Therapeutics, Inc. filed document, accession 0001193125-20-124813. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2020.

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU39,394$655,516—
RSU8,864$147,497—
Option75,731—$7.84
Option41,713—$16.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Fulcrum Therapeutics, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Fulcrum Therapeutics’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Robert GouldPresident and Chief Executive Officer$3,889,353
Owen Wallace · this pageChief Scientific Officer$1,559,523
Bryan StuartChief Operating Officer$1,234,960

The full Fulcrum Therapeutics compensation record

free company brief

This page is one person within Fulcrum Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Fulcrum Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Owen Wallace's compensation dossier · One-time report. No refunds.